CJC-1295 (no DAC)

CJC-1295 (no DAC) is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone (GHRH), engineered without the Drug Affinity Complex (DAC) to preserve the native pulsatile GH-secretion kinetics studied in neuroendocrine research. CAS 863288-34-0; molecular weight 3367.9 g/mol; supplied lyophilised at ≥99% purity by HPLC. For laboratory research use only; not for human or veterinary use.

Engineered to outlast the body's own rapid clearance of growth-hormone-releasing factor, CJC-1295 (no DAC) — also known as Modified GRF (1-29) — is a synthetic 29-amino-acid analogue of the bioactive N-terminal fragment of human growth-hormone-releasing hormone (GHRH). Critically, it is the variant without the Drug Affinity Complex (DAC), making it the lighter, shorter-acting tetrasubstituted peptide that has become a workhorse in endocrine signalling research.

A fragment refined, not reinvented. Native GRF(1-29) carries the full agonist activity of GHRH but is degraded within minutes, primarily by dipeptidyl peptidase IV (DPP-IV) cleaving its exposed N-terminus (Bai et al., 1995). To counter this, researchers introduced four targeted substitutions — most notably D-Ala at position 2 — yielding a backbone markedly more resistant to enzymatic breakdown while preserving receptor recognition. Unlike its DAC-bearing sibling, this form does not bind albumin, so its activity is comparatively transient.

What the research explores. The molecule has served as a probe for the GHRH receptor and the downstream GH/IGF-1 axis across several lines of inquiry:

• Receptor agonism & GH release — characterised as a long-acting GHRH analogue capable of stimulating growth-hormone secretion in model systems (Teichman et al., 2006; Alba et al., 2006).
• Pulsatility of secretion — studies probed whether continuous receptor stimulation preserves or blunts the natural pulsatile pattern of GH output (Ionescu et al., 2006).
• Bioconjugation & half-life extension — the GRF(1-29) scaffold has been a template for albumin-bioconjugate and PEGylation chemistry aimed at prolonging peptide residence (Jetté et al., 2005).
• Axis activation — work in animal models examined activation of the GH/IGF-1 axis and resulting serum profiles (Sackmann-Sala et al., 2009).

These findings derive exclusively from in vitro, animal, and early investigational studies; no conclusions regarding human use are supported. Full citations are listed under the Scientific References tab.

Physicochemical profile. CAS 863288-34-0 · Molecular formula C₁₅₂H₂₅₂N₄₄O₄₂ · Molecular weight 3367.9 · Sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ · Appearance: white lyophilized powder · Solubility: soluble in water.

Specification & quality. Each individually sealed vial contains 10 mg of CJC-1295 (no DAC) as a white lyophilized powder of ≥99% purity by HPLC. Every batch is third-party tested, with a Certificate of Analysis (COA) available. Store at −20 °C, protected from light and moisture. Shelf life: 24 months from the manufacture date.

This product is intended for laboratory research use only (RUO). It is not a drug, food, cosmetic, or dietary supplement, and is not for human or veterinary use, ingestion, or diagnostic application. Handling is restricted to qualified research professionals operating in an appropriately equipped laboratory.